CAR-T

Hospitals are saving lives with CAR-T. Getting paid is another story
Hospitals are saving lives with CAR-T. Getting paid is another story
Stat
CAR-T
drug pricing
cancer
hospitals
Flag link:
Beyond cancer: CAR T cells treat lupus in mice
Beyond cancer: CAR T cells treat lupus in mice
BioCentury
CAR-T
lupus
Flag link:
Xenetic Biosciences to Acquire Personalized CAR T Platform
Xenetic Biosciences to Acquire Personalized CAR T Platform
CP Wire
Xenetic Biosciences
CAR-T
Flag link:
Xenetic Biosciences to Acquire Personalized CAR T Platform
Xenetic Biosciences
CAR-T
Flag link:
Gilead’s Kite pens 10-target CAR-T tech deal with MaxCyte
Gilead’s Kite pens 10-target CAR-T tech deal with MaxCyte
Fierce Biotech
Gilead Sciences
Kite Pharma
CAR-T
MaxCyte
Flag link:
Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead
Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead
Endpoints
CAR-T
Gilead Sciences
UCLA
stem cells
Flag link:
Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Oncology round-up: CAR-T conference raises hopes for solid tumour therapy
Pharmaforum
CAR-T
CAR-T Congress
oncology
Novartis
Kymriah
Europe
Flag link:
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Fierce Pharma
Novartis
Kymriah
CAR-T
UK
diffuse large B-cell lymphoma
Gilead Sciences
Flag link:
Brexit could hinder CAR-T reimbursement in Europe
Brexit could hinder CAR-T reimbursement in Europe
Pharmaforum
Brexit
UK
Europe
CAR-T
Flag link:
Where Will bluebird bio Be in 5 Years?
Where Will bluebird bio Be in 5 Years?
Motley Fool
Bluebird Bio
LentiGlobin
bb21217
CAR-T
Flag link:
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
FDA
gene editing
Novartis
Sarepta Therapeutics
CAR-T
Alzheimer's disease
Flag link:
Celgene strikes Obsidian deal to boost CAR-T options
Celgene strikes Obsidian deal to boost CAR-T options
Fierce Biotech
Celgene
Obsidian Therapeutics
CAR-T
Flag link:
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
Yahoo/Reuters
Eli Lilly
Loxo Oncology
M&A
CAR-T
gene therapy
Flag link:
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises
Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises
Fierce Pharma
Novartis
Pharma CEOs
CAR-T
Kymriah
Vas Narasimhan
JPMHC 2019
Flag link:
Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T
Poseida pitches a $115M IPO on its claim that the science team has created a better BCMA CAR-T
Endpoints
Poseida Therapeutics
IPOs
BCMA
CAR-T
Flag link:
Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments
Poseida Therapeutics Prepares for IPO to Advance CAR-T Treatments
Xconomy
Poseida Therapeutics
CAR-T
IPOs
solid tumors
Flag link:
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
Xconomy
cancer
CAR-T
Gilead Sciences
Yescarta
Novartis
Kymriah
Flag link:
TCR2 Shoots for $100 Million IPO in Early 2019
TCR2 Shoots for $100 Million IPO in Early 2019
BioSpace
TCR2 Therapeutics
IPOs
CAR-T
Flag link:
Novartis seeks to acquire French CAR-T contract manufacturer
Novartis seeks to acquire French CAR-T contract manufacturer
Biopharma Dive
Novartis
M&A
France
CellforCure
CMO
Kymriah
CAR-T
Flag link:

Pages